In addition, through systemically analyzing the roles of m6A modifications in RA based on gene expression profiling data, novel targets were identified for RA clinical diagnosis and therapy, such as, Geng et al. found that IGF2BP3 and YTHDC2 could be used to diagnose RA accurately [112]. Here, IGF2BP3 is linked to rheumatoid arthritis.